{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T12:35:06Z","timestamp":1782218106169,"version":"3.54.5"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>This study is to evaluate the safety of two kinds of PCV13 carriers by monitoring the occurrence of adverse event following immunization (AEFI) after the launch of two kinds of PCV13 carriers in Jiangsu Province, China.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The AEFI Information System (CNAEFIS) of mainland China was used to monitor the incidence and classification of adverse reactions of the CRM197-carrier protein PCV13 and TT-carrier protein PCV13 vaccines.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There was no statistical difference between the cumulative reported incidence of AEFI between the two vaccines from 2020 to 2022 (<jats:italic>\u03c7<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u20091.991, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.158). 96.62% of the AEFIs were classified as common reactions; rare reactions and coincidental events only accounted for 2.99 and 0.39% of all the AEFI cases, respectively. Redness (2.6\u2009cm\u20135\u2009cm) is the commonest symptom at the injection site for both vaccines. More than 97% of AEFIs occurred between 30\u2009min and 3\u2009days after administration for both types of PCV13.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Both vaccines perform well in terms of safety. We did not identify any new\/unexpected safety concern from the NAEFISS during a 4\u2009years timespan.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2023.1272562","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T07:21:10Z","timestamp":1697440870000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Post-marketing safety surveillance for both CRM197 and TT carrier proteins PCV13 in Jiangsu, China"],"prefix":"10.3389","volume":"11","author":[{"given":"Ran","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanbao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guodong","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingma","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxiong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3760\/cma.j.cn112338-20201111-01322","article-title":"Chinese experts\u2019 consensus statement on diagnosis, treatment, and prevention of pneumococcal diseases in children","volume":"7","author":"Xiaochuan","year":"2020","journal-title":"Chin J Appl Clin Pediatr"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"24534","DOI":"10.1038\/s41598-021-03720-y","article-title":"Molecular surveillance of pneumococcal carriage following completion of immunization with the 13-valent pneumococcal conjugate vaccine administered in a 3+1 schedule","volume":"11","author":"Syrogiannopoulos","year":"2021","journal-title":"Sci Rep"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","year":"2022","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1080\/21645515.2020.1870396","article-title":"Cost-effectiveness analysis of domestic 13-valent pneumococcal conjugate vaccine for children under 5 years of age in mainland China","volume":"17","author":"Wang","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1016\/S0140-6736(22)02185-7","article-title":"Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the global burden of disease study 2019","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e744","DOI":"10.1016\/S2214-109X(18)30247-X","article-title":"Burden of Streptococcus pneumoniae and Haemophilus influenzae type B disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000\u20132015","volume":"6","author":"Wahl","year":"2018","journal-title":"Lancet Glob Health"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-2238-4","article-title":"Childhood vaccines and antibiotic use in low- and middle-income countries","volume":"581","author":"Lewnard","year":"2020","journal-title":"Nature"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.19914\/j.CJVI.2021001","article-title":"Expert consensus on influenza vaccination and pneumococcal vaccination for patients with certain chronic diseases (2020)","volume":"21","author":"Huaqing","year":"2021","journal-title":"Chin J Vacc Immun"},{"key":"ref9","volume-title":"Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper \u2013 February 2019","year":""},{"key":"ref10","year":"2022"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"9596129","DOI":"10.1155\/2020\/9596129","article-title":"The pneumococcal polysaccharide-tetanus toxin native C-fragment conjugate vaccine: the carrier effect and immunogenicity","volume":"2020","author":"Yu","year":"2020","journal-title":"Mediat Inflamm"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1097\/INF.0b013e31824b972b","article-title":"3007 study group. 13-valent pneumococcal conjugate vaccine given with meningococcal C-tetanus toxoid conjugate and other routine pediatric vaccinations: immunogenicity and safety","volume":"31","author":"Martin\u00f3n-Torres","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1186\/s12889-021-11387-3","article-title":"The characteristics and trend of adverse events following immunization reported by information system in Jiangsu province, China, 2015\u20132018","volume":"21","author":"Ran","year":"2021","journal-title":"BMC Public Health"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1093\/cid\/ciab645","article-title":"Dagan R; Israeli pediatric bacteremia and meningitis group (IPBMG); Israeli adult invasive pneumococcal disease (IAIPD) group. Dynamics of invasive pneumococcal disease in Israel in children and adults in the 13-valent pneumococcal conjugate vaccine (PCV13) era: a Nationwide prospective surveillance","volume":"74","author":"Ben-Shimol","year":"2022","journal-title":"Clin Infect Dis"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2010956","DOI":"10.1080\/20016689.2021.2010956","article-title":"Burden of illness associated with pneumococcal infections in Japan \u2013 a targeted literature review","volume":"10","author":"Igarashi","year":"2021","journal-title":"J Mark Access Health Policy"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/14760584.2023.2173176","article-title":"Economic evaluations of 13-valent pneumococcal conjugate vaccine: a systematic review","volume":"22","author":"Du","year":"2023","journal-title":"Expert Rev Vaccines"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e3778","DOI":"10.1093\/cid\/ciaa1483","article-title":"Nationwide trends of invasive pneumococcal disease in Spain from 2009 through 2019 in children and adults during the pneumococcal conjugate vaccine era","volume":"73","author":"de Miguel","year":"2021","journal-title":"Clin Infect Dis"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1124016","DOI":"10.3389\/fpubh.2023.1124016","article-title":"Epidemiology and serotype distribution of Streptococcus pneumoniae carriage among influenza-like illness cases in metropolitan Vientiane, Lao PDR: a community-based cohort study","volume":"11","author":"Sanchez Picot","year":"2023","journal-title":"Front Public Health"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"S109","DOI":"10.1097\/INF.0b013e318199f62d","article-title":"Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines","volume":"28","author":"Chevallier","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"ref20","article-title":"Adverse events following immunization: 6th international conference, GSES 2018, Handan, China, September 25\u201326, 2018, revised selected papers","author":"Li","year":"2019"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1184059","DOI":"10.3389\/fpubh.2023.1184059","article-title":"Analysis of 13-valent pneumococcal polysaccharide conjugate vaccine among children born in Hangzhou from 2017 to 2021","volume":"11","author":"Che","year":"2023","journal-title":"Front Public Health"},{"key":"ref22","first-page":"50","article-title":"Vaccination coverage of 13-valent pneumococcal conjugate vaccine among children born in 2017\u20132018 in Ningbo City, Zhejiang Province, China","volume":"33","author":"Lizhi","year":"2020","journal-title":"Clin JBiol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1080\/21645515.2021.1898306","article-title":"Surveillance of adverse events following the introduction of inactivated poliovirus vaccine made from Sabin strains (sIPV) to the Chinese EPI and a comparison with adverse events following inactivated poliovirus vaccine made from wild strains (wIPV) in Jiangsu","volume":"17","author":"Kang","year":"2021","journal-title":"China Hum Vaccin Immunother"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2021711","DOI":"10.1080\/21645515.2021.2021711","article-title":"Surveillance on the adverse events following immunization with the pentavalent vaccine in Zhejiang, China","volume":"18","author":"Pan","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.vaccine.2021.01.048","article-title":"Post-marketing safety surveillance for inactivated enterovirus 71 vaccines in Jiangsu, China from 2017 to 2019","volume":"39","author":"Gao","year":"2021","journal-title":"Vaccine"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1093\/tropej\/fmz004","article-title":"Safety comparison of two enterovirus 71 (EV71) inactivated vaccines in Yiwu (65, 545, 2019)","volume":"65","author":"Luo","year":"2020","journal-title":"J Trop Pediatr"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1586\/erv.09.59","article-title":"Pediatric combined formulation DTaP-IPV\/Hib vaccine","volume":"8","author":"White","year":"2009","journal-title":"Expert Rev Vaccines"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1272562\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T07:21:15Z","timestamp":1697440875000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1272562\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,16]]},"references-count":27,"alternative-id":["10.3389\/fpubh.2023.1272562"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2023.1272562","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,16]]},"article-number":"1272562"}}